Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial
Nita Bhandari, Temsunaro Rongsen-Chandola, Ashish Bavdekar, Jacob John, Kalpana Antony, Sunita Taneja, Nidhi Goyal, Anand Kawade, Gagandeep Kang, Sudeep Singh Rathore, Sanjay Juvekar, Jayaprakash Muliyil, Alok Arya, Hanif Shaikh, Vinod Abraham, Sudhanshu Vrati, Michael Proschan, Robert Kohberger, Georges Thiry, Roger Glass, Harry B Greenberg, George Curlin, Krishna Mohan, G V J A Harshavardhan, Sai Prasad, T S Rao, John Boslego, Maharaj Kishan Bhan, India Rotavirus Vaccine Group, Krishna M Ella, Madhu Mahesh, Farhana Afzal Rafiqi, Girish Dayma, Anand Pandit, Anuradha Bose, Vinohar Balraj, Deepak More, Pankaj Ghatbandhe, Taranjeet Kaur, Sharan Basava, Sudhir Babji, Amit Mohindru, Manju Bagdwal, Elizabeth Horigan, Margaret Wecker, Jorge Flores, David Alli, Kårstein Måseide, Unni Hirdman, Tor A Strand, Balaji K Ananth, Mathuram Santosham, Olivier Fontaine, Lawrence Moulton, Satinder Aneja, Nik Zarifah Nik Hussain Reed, Veereshwar Bhatnagar, Arun Kumar Gupta, Madhulika Kabra, Siddharth Ramji, Amita Sapru, Prabhakar Moses, Nita Bhandari, Temsunaro Rongsen-Chandola, Ashish Bavdekar, Jacob John, Kalpana Antony, Sunita Taneja, Nidhi Goyal, Anand Kawade, Gagandeep Kang, Sudeep Singh Rathore, Sanjay Juvekar, Jayaprakash Muliyil, Alok Arya, Hanif Shaikh, Vinod Abraham, Sudhanshu Vrati, Michael Proschan, Robert Kohberger, Georges Thiry, Roger Glass, Harry B Greenberg, George Curlin, Krishna Mohan, G V J A Harshavardhan, Sai Prasad, T S Rao, John Boslego, Maharaj Kishan Bhan, India Rotavirus Vaccine Group, Krishna M Ella, Madhu Mahesh, Farhana Afzal Rafiqi, Girish Dayma, Anand Pandit, Anuradha Bose, Vinohar Balraj, Deepak More, Pankaj Ghatbandhe, Taranjeet Kaur, Sharan Basava, Sudhir Babji, Amit Mohindru, Manju Bagdwal, Elizabeth Horigan, Margaret Wecker, Jorge Flores, David Alli, Kårstein Måseide, Unni Hirdman, Tor A Strand, Balaji K Ananth, Mathuram Santosham, Olivier Fontaine, Lawrence Moulton, Satinder Aneja, Nik Zarifah Nik Hussain Reed, Veereshwar Bhatnagar, Arun Kumar Gupta, Madhulika Kabra, Siddharth Ramji, Amita Sapru, Prabhakar Moses
Abstract
Background: Rotavirus is the most common cause of severe dehydrating gastroenteritis in developing countries. Safe, effective, and affordable rotavirus vaccines are needed in these countries. We aimed to assess the efficacy and tolerability of a monovalent human-bovine rotavirus vaccine for severe rotavirus gastroenteritis in low-resource urban and rural settings in India.
Methods: We did a randomised double-blind, placebo-controlled, multicentre trial at three sites in Delhi (urban), Pune (rural), and Vellore (urban and rural) between March 11, 2011, and Nov 5, 2012. Infants aged 6-7 weeks were randomly assigned (2:1), via a central interactive voice or web response system with a block size of 12, to receive either three doses of oral human-bovine natural reassortant vaccine (116E) or placebo at ages 6-7 weeks, 10 weeks, and 14 weeks. Infants' families, study investigators, paediatricians in referral hospitals, laboratory staff, and committee members were all masked to treatment allocation. The primary outcome was incidence of severe rotavirus gastroenteritis (≥11 on the Vesikari scale). Efficacy outcomes and adverse events were ascertained through active surveillance. Analysis was by intention to treat and per protocol. The trial is registered with Clinical Trial Registry-India (CTRI/2010/091/000102) and ClinicalTrials.gov (NCT01305109).
Findings: 4532 infants were assigned to receive the 116E vaccine and 2267 to receive placebo, of whom 4354 (96%) and 2187 (96%) infants, respectively, were included in the primary per-protocol efficacy analysis. 71 events of severe rotavirus gastroenteritis were reported in 4752 person-years in infants in the vaccine group compared with 76 events in 2360 person-years in those in the placebo group; vaccine efficacy against severe rotavirus gastroenteritis was 53·6% (95% CI 35·0-66·9; p=0·0013) and 56·4% (36·6-70·1; p<0·0001) in the first year of life. The number of infants needed to be immunised to prevent one severe rotavirus gastroenteritis episode was 55 (95% CI 37-97). The incidence of severe rotavirus gastroenteritis per 100 person-years was 1·5 in the vaccine group and 3·2 in the placebo group, with an incidence rate ratio of 0·46 (95% CI 0·33-0·65). Prevalence of immediate, solicited, and serious adverse events was similar in both groups. One case of urticaria in the vaccine group and one each of acute gastroenteritis and suspected sepsis in the placebo group were regarded as related to the study product. We recorded six cases of intussusception in the vaccine group and two in the placebo group, all of which happened after the third dose. 25 (<1%) infants in the vaccine group and 17 (<1%) in the placebo group died; no death was regarded as related to the study product.
Interpretation: Monovalent human-bovine (116E) rotavirus vaccine is effective and well tolerated in Indian infants.
Funding: Department of Biotechnology and the Biotechnology Industry Research Assistance Council, Government of India; Bill & Melinda Gates Foundation to PATH, USA; Research Council of Norway; UK Department for International Development; National Institutes of Health, Bethesda, USA; and Bharat Biotech International, Hyderabad, India.
Conflict of interest statement
CONFLICT OF INTEREST
KM, GVJAH and SP are employees of Bharat Biotech International Limited. Other authors have no conflict of interest.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Figures
Source: PubMed